Galapagos NV

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications.  We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world.  Galapagos is focused on the development and commercialization of novel medicines that will improve people’s lives. Galapagos, has approximately 374 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands and France. 
More information at www.glpg.com.

Contact Galapagos NV

Generaal de Wittelaan L11A3

2800 Mechelen

Telephone:  015 342 841

els.klerkx@glpg.com

http://www.glpg.com

Saved Jobs